<?xml version="1.0" encoding="UTF-8"?>
<p>More complicated and realistic models previously limited by computing capability can be developed with the advances of computing power [
 <xref rid="B137-vaccines-07-00045" ref-type="bibr">137</xref>]. For example, it becomes possible to develop viral phylodynamic models that can incorporate results from laboratory experiments of viral antigens and host immune responses [
 <xref rid="B108-vaccines-07-00045" ref-type="bibr">108</xref>]; The development on structured coalescent for better estimation on viral population and mutation or migration events [
 <xref rid="B138-vaccines-07-00045" ref-type="bibr">138</xref>,
 <xref rid="B139-vaccines-07-00045" ref-type="bibr">139</xref>]. Furthermore, to avoid overparameterization, model selection procedure should be applied during the process of novel model development to optimize the balance of biological reality and parameterization [
 <xref rid="B137-vaccines-07-00045" ref-type="bibr">137</xref>,
 <xref rid="B140-vaccines-07-00045" ref-type="bibr">140</xref>]. With all these, the next step would be to introduce and apply machine learning to the computational process for vaccine design. 
</p>
